4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cogent Biosciences, Inc. (COGT) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 258 employees. Its market capitalization is roughly $7 billion. In the fiscal year ended 2025-12-31, COGT reported $0M in revenue and ($329M) in net income.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($333M) | ($276M) | ($208M) | ($148M) | — |
| Net Income | ($329M) | ($256M) | ($192M) | ($140M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($104M) | ($100M) | ($83M) | ($76M) | ($75M) |
| Net Income | ($97M) | ($102M) | ($81M) | ($74M) | ($72M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $938M | $328M | $313M | $301M | — |
| Total Liabilities | $301M | $72M | $56M | $45M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive COGT viewer.
About TickerBase · Data methodology & sources